2024
Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ProtozoanBabesia microtiBabesiosisEnzyme-Linked Immunosorbent AssayHumansImmunoglobulins, IntravenousConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samples
2023
Transfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation
Drews S, Kjemtrup A, Krause P, Lambert G, Leiby D, Lewin A, O'Brien S, Renaud C, Tonnetti L, Bloch E. Transfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation. Journal Of Clinical Microbiology 2023, 61: e01268-22. PMID: 37750699, PMCID: PMC10595070, DOI: 10.1128/jcm.01268-22.Peer-Reviewed Original ResearchConceptsBlood productsWhole blood-derived platelet concentratesNon-endemic areasNon-endemic regionsTTB casesMost patientsRed blood cellsClinical presentationSevere illnessBlood donorsDead-end hostsTick-borne parasitesHuman transmissionEndemic regionsClinical settingEpidemiologyBlood cellsCase numbersPlatelet concentratesTransfusionRiskNeurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
Locke S, O’Bryan J, Zubair A, Rethana M, Moffarah A, Krause P, Farhadian S. Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1127-1135. PMID: 37209667, PMCID: PMC10202888, DOI: 10.3201/eid2906.221890.Peer-Reviewed Original ResearchMeSH KeywordsAdultBabesia microtiBabesiosisConnecticutHumansNervous System DiseasesParasitemiaUnited StatesConceptsNeurologic complicationsNeurologic symptomsRisk factorsYale-New Haven HospitalInfectious Diseases journal - CDCHigh-grade parasitemiaNeurologic risk factorsRange of symptomsAdult patientsRenal failureDiabetes mellitusFrequent symptomsHospital admissionImpaired consciousnessMedical recordsEndemic areasParasitic infectionsPatientsSymptomsIntraerythrocytic protozoaComplicationsBabesiosisNew HavenDeliriumMellitusThe impact of ABO and RhD blood types on Babesia microti infection
Jajosky R, O’Bryan J, Spichler-Moffarah A, Jajosky P, Krause P, Tonnetti L. The impact of ABO and RhD blood types on Babesia microti infection. PLOS Neglected Tropical Diseases 2023, 17: e0011060. PMID: 36696414, PMCID: PMC9901808, DOI: 10.1371/journal.pntd.0011060.Peer-Reviewed Original ResearchConceptsB. microti infectionABO blood typeBabesia microti infectionMicroti infectionBlood donorsBlood typeDisease severityPlasmodium falciparum malaria patientsFalciparum malaria patientsHigher peak parasitemiaRed blood cell antigensType BImpact of ABOBlood cell antigensBlood type BMalaria patientsTransfusion strategyInfected donorsRhD blood typeSevere diseasePeak parasitemiaB antigensCell antigensPossible associationRhD antigen
2022
Cardiac Complications of Human Babesiosis
Spichler-Moffarah A, Ong E, O’Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2022, 76: e1385-e1391. PMID: 35983604, PMCID: PMC10169432, DOI: 10.1093/cid/ciac525.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalCardiac complicationsRisk factorsIntensive care unit stayCardiovascular disease risk factorsHuman babesiosisCommon cardiac complicationHigh-grade parasitemiaLife-threatening complicationsDisease risk factorsLonger median lengthQT interval prolongationHigh mortality rateUnit stayComplication groupTick-borne diseaseAdult patientsCardiac outcomesMost patientsThin blood smearsHeart failureInterval prolongationModerate illnessRecord reviewAtrial fibrillation
2021
Recurrence of Human Babesiosis Caused by Reinfection - Volume 27, Number 10—October 2021 - Emerging Infectious Diseases journal - CDC
Ho J, Carey E, Carey DE, Krause PJ. Recurrence of Human Babesiosis Caused by Reinfection - Volume 27, Number 10—October 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 2659-2661. PMID: 34546166, PMCID: PMC8462340, DOI: 10.3201/eid2710.211240.Peer-Reviewed Original Research
2020
Antigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens
Verma N, Puri A, Essuman E, Skelton R, Anantharaman V, Zheng H, White S, Gunalan K, Takeda K, Bajpai S, Lepore TJ, Krause PJ, Aravind L, Kumar S. Antigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens. Scientific Reports 2020, 10: 9598. PMID: 32533024, PMCID: PMC7293334, DOI: 10.1038/s41598-020-66273-6.Peer-Reviewed Original ResearchConceptsPotential biological functionsBiological functionsCellular localization studiesB. microtiEvolutionary relationshipsDomain architectureBioinformatics analysisRecombinant proteinsExtracellular domainLocalization studiesPrimary causative agentUnrelated groupsE. coliBiological characterizationNovel assayIntraerythrocytic parasitesBabesia microtiDistinct classesProteinCausative agentAntigen discoveryGlobal public health impactB. microti antibodiesB. microti antigenTransfusion of bloodClofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts
Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. The Journal Of Infectious Diseases 2020, 222: 1027-1036. PMID: 32310272, DOI: 10.1093/infdis/jiaa195.Peer-Reviewed Original ResearchConceptsB. microti parasitesMicroti infectionHigh-grade parasitemiaDrug-resistant tuberculosisB. microtiBabesia microti infectionAdditional preclinical studiesB. microti infectionImmunocompromised hostB. microti DNAPolymerase chain reactionPreclinical studiesIncidence of babesiosisPromising drugRadical cureMinimal doseClofazimineDay 10Blood smearsBabesia microtiNovel drugsParasitemiaChain reactionMicroscopic examinationAntimicrobial agents
2019
Repeat exchange transfusion for treatment of severe babesiosis
Radcliffe C, Krause PJ, Grant M. Repeat exchange transfusion for treatment of severe babesiosis. Transfusion And Apheresis Science 2019, 58: 638-640. PMID: 31526674, DOI: 10.1016/j.transci.2019.07.010.Peer-Reviewed Case Reports and Technical NotesConceptsRepeat exchange transfusionExchange transfusionSevere babesiosisHospital day 5Second exchange transfusionBabesia microti infectionHigh feverRheumatoid arthritisMicroti infectionTransfusionDay 5Literature searchDearth of informationParasitemiaInfectionBabesiosisEtanerceptArthritisFeverClindamycinHypoxiaCasesWeeksWomen
2018
BmGPAC, an Antigen Capture Assay for Detection of Active Babesia microti Infection
Thekkiniath J, Mootien S, Lawres L, Perrin BA, Gewirtz M, Krause PJ, Williams S, Doggett J, Ledizet M, Mamoun C. BmGPAC, an Antigen Capture Assay for Detection of Active Babesia microti Infection. Journal Of Clinical Microbiology 2018, 56: 10.1128/jcm.00067-18. PMID: 30093394, PMCID: PMC6156295, DOI: 10.1128/jcm.00067-18.Peer-Reviewed Original ResearchConceptsHuman babesiosisBabesia microti infectionCapture enzyme-linked immunosorbent assayAntigen capture enzyme-linked immunosorbent assayAntigen capture assayEnzyme-linked immunosorbent assayZoonotic infectious diseaseAcute infectionBlood transfusionAsymptomatic infectionMicroti infectionReal-time PCRBlood supplyAnimal reservoir hostsDonor bloodEpidemiological surveyHuman patientsImmune systemSerological assaysImmunodominant antigensInfectionInfectious diseasesIntraerythrocytic protozoan parasitePatientsImmunosorbent assaySuperior real‐time polymerase chain reaction detection of Babesia microti parasites in whole blood utilizing high‐copy BMN antigens as amplification targets
Grabias B, Clement J, Krause PJ, Lepore T, Kumar S. Superior real‐time polymerase chain reaction detection of Babesia microti parasites in whole blood utilizing high‐copy BMN antigens as amplification targets. Transfusion 2018, 58: 1924-1932. PMID: 29664114, DOI: 10.1111/trf.14642.Peer-Reviewed Original ResearchMeSH KeywordsAntigensBabesia microtiBlood DonorsHumansReal-Time Polymerase Chain ReactionTransfusion ReactionConceptsParasites/mLBlood donorsBlood samplesSeroreactive antigensBabesia microti parasitesWhole bloodTransfusion-transmitted infectionsParasite nucleic acidsReal-time polymerase chain reactionWhole blood samplesPolymerase chain reaction detectionPolymerase chain reactionSensitive molecular assaysBlood productsClinical characterizationRT-PCR detectionReal-time polymerase chain reaction detectionLaboratory diagnosisBabesia microtiStudy designInfected ticksDilution panelsAntigenZoonotic diseaseBlood
2017
Case report of the patient source of the Babesia microti R1 reference strain and implications for travelers
Stahl P, Poinsignon Y, Pouedras P, Ciubotaru V, Berry L, Emu B, Krause PJ, Mamoun C, Cornillot E. Case report of the patient source of the Babesia microti R1 reference strain and implications for travelers. Journal Of Travel Medicine 2017, 25: tax073. PMID: 29394381, PMCID: PMC6927858, DOI: 10.1093/jtm/tax073.Peer-Reviewed Original ResearchConceptsIndirect immunofluorescence antibody testingBabesiosis casesB. microti antibodiesB. microtiTreatment of babesiosisImmunofluorescence antibody testingB. microti infectionNon-endemic areasDiagnosis of babesiosisMicroti antibodiesFebrile illnessImmunocompetent patientsRed blood cellsAntibody testingB. microti DNAPhysical examinationCase reportMedical historyMicroti infectionTick biteClinical informationEndemic areasPatient sourcePatientsBlood smears
2016
Transfusion-transmitted babesiosis
Levin AE, Krause PJ. Transfusion-transmitted babesiosis. Current Opinion In Hematology 2016, 23: 573-580. PMID: 27537475, PMCID: PMC5241272, DOI: 10.1097/moh.0000000000000287.Peer-Reviewed Original ResearchConceptsTransfusion-transmitted babesiosisBlood donorsB. microti antibodiesInfectious blood donorsAssociated mortality rateOptimal screening strategyTransfusion-transmitted pathogensSignificant health burdenAvailable screening toolsUnited States populationPathogen inactivation methodsMicroti antibodiesSevere illnessHealth burdenMortality rateUS FoodDrug AdministrationBabesia microtiScreening toolLaboratory screeningScreening strategyBabesiosisInactivation methodPCR assaysRecent studies
2015
Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences
Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences. Trends In Parasitology 2015, 32: 30-42. PMID: 26613664, PMCID: PMC4713283, DOI: 10.1016/j.pt.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArachnid VectorsBabesia microtiBabesiosisBorrelia burgdorferiCoinfectionHumansIxodesLyme DiseaseConceptsB. microtiDisease severityGreater disease severityEnzootic cycleCoinfected individualsTick-borne pathogenClinical consequencesTherapeutic strategiesLyme diseaseBabesia microtiHost factorsCoinfectionBorrelia burgdorferiB. burgdorferiIxodes ticksMicrotiReservoir hostsSeverityHuman pathogensBurgdorferi
2014
Monitoring Human Babesiosis Emergence through Vector Surveillance New England, USA - Volume 20, Number 2—February 2014 - Emerging Infectious Diseases journal - CDC
Diuk-Wasser MA, Liu Y, Steeves TK, Folsom-O'Keefe C, Dardick KR, Lepore T, Bent SJ, Usmani-Brown S, Telford SR, Fish D, Krause PJ. Monitoring Human Babesiosis Emergence through Vector Surveillance New England, USA - Volume 20, Number 2—February 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 225-231. PMID: 24447577, PMCID: PMC3901474, DOI: 10.3201/eid2002.130644.Peer-Reviewed Original ResearchConceptsHuman babesiosisInfectious Diseases journal - CDCProtozoan Babesia microtiDisease-endemic areasTick-borne diseaseBabesiosis-endemic areasSame tick vectorInfection rateInfection ratioTick infection ratesLyme diseaseBabesia microtiHuman casesDiseaseDisease expansionBabesiosisReservoir hostsTick vectorHuman diseasesSurveillanceClose association
2012
Human Babesiosis
Vannier E, Krause PJ. Human Babesiosis. New England Journal Of Medicine 2012, 366: 2397-2407. PMID: 22716978, DOI: 10.1056/nejmra1202018.Peer-Reviewed Original ResearchPreventing transfusion‐transmitted babesiosis: preliminary experience of the first laboratory‐based blood donor screening program
Young C, Chawla A, Berardi V, Padbury J, Skowron G, Krause PJ, Group T. Preventing transfusion‐transmitted babesiosis: preliminary experience of the first laboratory‐based blood donor screening program. Transfusion 2012, 52: 1523-1529. PMID: 22452654, DOI: 10.1111/j.1537-2995.2012.03612.x.Peer-Reviewed Original ResearchConceptsTransfusion-transmitted babesiosisCases of TTBPolymerase chain reactionBlood donorsThalassemia patientsCommon transfusion-transmitted infectionSickle cellsIndeterminate PCR resultsPositive IFA resultsTransfusion-transmitted infectionsInvestigational new drug applicationReal-time polymerase chain reactionUnscreened bloodDonor screeningPatientsIFA resultsDrug AdministrationNew drug applicationsPreliminary experienceIndirect immunofluorescenceBabesia microtiStudy designDrug applicationChain reactionPCR results
2010
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 2010, 50: 381-386. PMID: 20047477, DOI: 10.1086/649859.Peer-Reviewed Original ResearchConceptsDrug regimenB. microtiLevel of immunosuppressionBabesia microti infectionTreatment of babesiosisDrug-resistant strainsEmergence of resistanceActive babesiosisMicrobiologic relapseLaboratory abnormalitiesDrug regimensImmunocompromised patientsOptimal therapyTreatment failureDrug therapyMicroti infectionPatientsClinical case historiesDrug resistanceBabesia microtiInfectionRegimenMicrotiEventual developmentBabesiosis
2007
ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT
Raju M, Salazar JC, Leopold H, Krause PJ. ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT. The Pediatric Infectious Disease Journal 2007, 26: 181-183. PMID: 17259886, DOI: 10.1097/01.inf.0000250622.11505.8f.Peer-Reviewed Original ResearchConceptsCyanotic heart diseaseBabesia microti infectionTreatment of childrenOral azithromycinThin blood smearsInitial presentationSevere anemiaHeart diseaseMicroti infectionPolymerase chain reactionHepatic enzymesBlood smearsInfantsIntraerythrocytic parasitesChain reactionTreatmentBabesiosisLaboratory testsFebrileThrombocytopeniaCyanoticAnemiaClindamycinSerologyAzithromycin
2003
Babesiosis in Pregnancy
Feder HM, Lawlor M, Krause PJ. Babesiosis in Pregnancy. New England Journal Of Medicine 2003, 349: 195-196. PMID: 12853599, DOI: 10.1056/nejm200307103490221.Peer-Reviewed Original Research